Table 1 Patient and Tumour Characteristics at initial diagnosis
From: Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Subgroup | Total Group(55) | BEVstart(28) | BEVreject(15) |
|---|---|---|---|
Age | |||
< 50 | 12 | 7 | 3 |
> 50 | 43 | 21 | 12 |
Gender | |||
Male | 31 | 12 | 13 |
Female | 24 | 16 | 2 |
Site of Tumour | |||
Frontal | 18 | 10 | 6 |
Temporal | 13 | 8 | 3 |
Parietal | 19 | 7 | 5 |
Occipital | 3 | 3 | 0 |
Other | 2 | 0 | 1 |
Extent of Resection | |||
Near Total | 28 | 15 | 6 |
Subtotal | 18 | 9 | 7 |
Biopsy | 9 | 4 | 2 |
ECOG at initial RT | |||
0,1 | 43 | 22 | 11 |
2,3 | 12 | 6 | 4 |
MGMT | |||
Methylated | 12 | 9 | 2 |
Unmethylated | 16 | 4 | 2 |
Unknown | 27 | 15 | 11 |